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ABSTRACT
Background We aimed to assess the impact of genomic
human leukocyte antigen (HLA)-I/II homozygosity on
the survival benefit of patients with unresectable locally
advanced, metastatic non-small lung cancer treated
by single-agent programmed cell death protein-1/
programmed death ligand 1 (PD1/PDL1) inhibitors.
Methods We collected blood from 170 patients with
advanced lung cancer treated with immunotherapy at two
major oncology centers in Western Australia. Genomic DNA
was extracted from white blood cells and used for HLA-I/
II high-resolution typing. HLA-I/II homozygosity was tested
for association with survival outcomes. Univariable and
multivariable Cox regression models were constructed to
determine whether HLA homozygosity was an independent
prognostic factor affecting Overall Survival (OS) and
Progression Free Survival (PFS). We also investigated the
association between individual HLA-A and -B supertypes
with OS.
Results Homozygosity at HLA-I loci, but not HLA-II, was
significantly associated with shorter OS (HR=2.17, 95% CI
1.13 to 4.17, p=0.02) in both univariable and multivariable
analysis. The effect of HLA-I homozygosity in OS was
particularly relevant for patients with tumors expressing
PDL1 ≥50% (HR=3.93, 95% CI 1.30 to 11.85, p<0.001).
The adverse effect of HLA-I homozygosity on PFS was only
apparent after controlling for interactions between PDL1
status and HLA-I genotype (HR=2.21, 95% CI 1.04 to 4.70,
p=0.038). The presence of HLA-A02 supertype was the
only HLA-I supertype to be associated with improved OS
(HR=0.56, 95% CI 0.34 to 0.93, p=0.023).
Conclusion Our results suggest that homozygosity at ≥1
HLA-I loci is associated with short OS and PFS in patients
with advanced non-small cell lung cancer with PDL1
≥50% treated with single-agent immunotherapy. Carriers
of HLA-A02 supertype reported better survival outcomes in
this cohort of patients.

BACKGROUND
Lung cancer is the second most common
cancer worldwide in 2019 and the leading
cancer-
related cause of death among both
men and women.1 While the introduction
of immunotherapy into the treatment of

advanced and metastatic non-small cell lung
cancer (NSCLC) has improved survival when
compared with chemotherapy, the 5 years
survival rate continues to be as low as 23.2%
and 15.5% in the first-line and second-line
setting, respectively.2 While programmed
death ligand (PDL1) expression on tumor
cells is to date the only FDA (Food and
Drug Administration) approved biomarker
of response to anti-programmed cell death
protein-1/programmed death ligand 1 (PD1/
PDL1) therapies, the 3-year and 5-year survival
remains suboptimal even in patients with
PDL1 expression on more than 50% of the
viable tumor cells, that is, their tumor proportion score (TPS) is ≥50%.2 3 Therefore, tumor
PDL1 expression cannot be used as the only
biomarker to predict response and survival in
patients treated with anti-PD1/PDL1 therapy.
There is ongoing research to identify affordable and easily obtained biomarkers that can
be used as adjunct to tumor PDL1 expression
for precision medicine.
Human leukocyte antigen (HLA) is
expressed on somatic as well as immune
cells. HLA molecules introduce internally
processed cellular antigens to T lymphocytes to trigger a series of signals to activate
or inhibit T cell proliferation and differentiation.4 5 HLA molecules are divided into two
types, HLA-I and HLA-II. HLA-I is expressed
on all nucleated cells, including somatic,
cancer and immune cells and presents cell
peptides to activate CD8+T cells. HLA-
II,
on the other hand, is expressed on antigen-
presenting cells and mediates the activation of
CD4+ helper or regulatory T cells. HLA molecules are encoded by the HLA gene complex
located on the short arm of chromosome 6 at
locus 21 (6p21).6 7 The HLA locus is not only
polygenic but also highly polymorphic with
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each locus having multiple alleles.8 9 HLA alleles can be
grouped based on their peptide-binding repertoire into
supertypes.10 Only HLA-A and HLA-B supertypes are well-
characterized, with Sidney et al (2008) describing nine
supertypes for HLA-A and HLA-B alleles based on their
specificity for the anchor amino acids.10
HLA molecule downregulation in cancer tissue is
a well-
established mechanism of cancer evading the
immune system.11–15 The low expression or low diversity
of HLA on the cell surface is directly related to the range
of antigens that can be presented to T cells. Many studies
have looked at the correlation between expressed HLA-I
on tumor cells and its effect on survival and response
to immunotherapy.16–22 However, the effect of low HLA
genetic diversity (or homozygosity) on response to immunotherapy has not been explored, with the exception of
two recent studies.23 24 Chowell et al investigated the relationship between genetic HLA homozygosity and survival
in 100 NSCLC and 269 patients with melanoma treated
with immunotherapy, either with anti-PD1/PDL1 or anti-
CTLA4 or both. Reduced survival was correlated with
homozygosity in at least one HLA-I locus. Therefore, it was
postulated that maximal heterozygosity of HLAs might
be associated with higher diversity of antigens presented
to the T cells, compared with an individual with homozygosity at one or more HLA loci.23 Furthermore, they
observed that HLA-
B62 supertype was strongly associated with reduced survival, while the HLA-B44 supertype
associated with longer survival.23 Hence genomic HLA
can be explored as an economical and easily obtained
non-invasive biomarker that can help guide treatment
choice among patients with NSCLC patients treated with
immunotherapy.
Here, we aim to assess whether homozygosity in HLA-I
or HLA-II is associated with survival outcomes among
patients with advanced NSCLC treated with single agent
anti-programmed cell death protein-1 (PD1) or anti-PDL1
therapy in the first-line or second-line setting.
METHODS
Patients
Patients were recruited from two major teaching hospitals in Western Australia. Recruited patients were 18 years
or older, diagnosed with unresectable locally advanced
NSCLC and treated with single agent pembrolizumab,
atezolizumab or nivolumab in the first-line or the second-
line setting. Given that genomic HLA would not be altered
by infection, treatment or any other environmental
factors, patients were recruited both prospectively and
retrospectively. Patient demographics and clinicopathological features that may affect outcome were collected
from the clinical records and included: age, Eastern
Cooperative Oncology Group (ECOG) performance
status and smoking status. Pre-
treatment neutrophil/
lymphocyte ratio (NLR) was calculated using the pre-
treatment full blood count (FBC) results. Tumor characteristics included: histopathology, PDL1 expression and
2

genetic alterations (epidermal growth factor receptor
associated
(EGFR) mutations, echinoderm microtubule-
protein like-4-anaplastic lymphoma kinase (EML4/ALK)
fusion, c-ros oncogene 1 (ROS1) fusions and Kirsten RAt
Sarcoma (KRAS) GTPase mutations). The latter was only
performed in NSCLC with non-squamous cell carcinoma
histology.
DNA extraction and genomic HLA-typing
Blood was collected in EDTA blood tubes, and either
stored as whole blood or white blood cell pellet in a
freezer at −80°C. QIAamp DNA Blood Maxi Kit was used
for DNA extraction. Extracted DNA was used for high-
resolution HLA typing at the Institute of Immunology
and Infectious disease (IIID) at Murdoch University.
HLA testing at IIID has been accredited by the American Society for Histocompatibility and Immunogenetics
(ASHI) and the National Association of Testing Authorities (NATA). Specific HLA loci on the extracted DNA are
PCR amplified using sample-specific molecular indexed
primers (MID-tagged) that amplify polymorphic exons
from Class I (A, B, C Exons 2 and 3) and Class II (DQ,
Exons 2 and 3; DRB and DPB1, Exon 1) HLA genes. MID-
tagged primers have been optimized to minimize allele
dropouts and primer bias. Amplified DNA products from
unique MID-tagged products are pooled in equimolar
ratios and subjected to library preparation. Post QC and
quantitation the normalized libraries are then sequenced
on the Illumina MiSeq platform using the MiSeq V3 600-
cycle kit (2×300 bp reads). Sequences are separated by
MID tags and alleles called using an in-house accredited
HLA allele caller software pipeline that minimizes the
influence of sequencing errors. Alleles are called using
the latest IMGT HLA allele database as the allele reference library. Sample to report integrity was tracked and
checked using proprietary and accredited Laboratory
Information and Management System and HLA analyze
reporting software that performs comprehensive allele
balance and contamination checks on the final data set.25
Genomic HLA-A and HLA-B alleles were classified into
supertypes using the method described by Sidney et al.10
PDL1 analysis
Immunohistochemistry, using the Dako 22C3 clone for
all patients, for PDL1 testing was performed by PathWest
Pathology Services as per standard diagnostic services and
reported as TPS.
Statistical analysis
Progression free survival (PFS) was defined as the time
interval between the start of therapy and the date of first
progression/death. Progression was determined by clinician assessment based on both radiological and clinical
presentation of the patient. Overall survival (OS) was
defined as the time between the start of immunotherapy
and death. The minimum follow-up time was 6 months.
Those who did not experience disease progression or
Abed A, et al. J Immunother Cancer 2020;8:e001620. doi:10.1136/jitc-2020-001620
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were still alive at the time of analysis (January 2020) were
censored.
Patients were dichotomised based on HLA homozygosity at one or more loci and heterozygosity; or based on
the presence of specific HLA-A and HLA-B supertypes.
PFS and OS were compared between groups using log-
rank (Mantel-
Cox) test and Kaplan-
Meier plots using
GraphPad Prism V.8 (GraphPad Software, Inc, San Diego,
California).
A power calculation was carried out assuming a
frequency of homozygosity in one HLA loci in the general
population of around 20%, with a median follow-
up
period of 36 months from the time of starting immunotherapy, and a median survival for homozygous patients
of approximately 12 months (based on Chowell et al
2018 cohort 1).23 If the true HR is 2 for overall survival
of homozygotes relative heterozygotes, 161 patients will
be sufficient to reject the null hypothesis with probability
0.86 and a Type I error probability of 0.05.
Cox regression analyzes were used to compare the effect
of HLA-I homozygosity on OS outcomes in subgroups
of patients stratified according to age, sex, PDL1 tumor
proportion score, pre-
treatment NLR, ECOG performance scores, smoking status, histopathology, the presence of KRAS mutations (only among non-squamous cell
carcinoma (non-SCC) cases), therapy modality and line
of treatment.
We conducted univariable and multivariable analyzes
using Cox regression models in SPSS V.25 (IBM, Armonk,
New York) correlating HLA homozygosity with PFS and
OS and controlling for tumor PDL1, pre-
treatment
NLR, age, ECOG status and therapy type (anti-PD1 and
anti-PDL1). As the expression of PDL1 protein on cancer
cells might be dependent on the first signal of interaction
between HLA-I molecule on tumor cells and the T-cell
receptor (TCR), we investigated the interactions between
HLA homozygosity and tumor PDL1 expression and to
reduce the effect of different confounders on the studied
variable.

Table 1 Demographics and disease characteristics of
patients at baseline
Full cohort PDL1 known group
N (%)
N (%)
Age
 ≥65

92 (57)

70 (61)

 <65

69 (43)

44 (39)

 M

90 (56)

66 (58)

 F

71 (44)

48 (42)

Sex

ECOG
 ≤1

137 (85)

96 (84)

 >1

23 (14)

17 (15)

2 (1)

1 (1)

 Yes

131 (81)

91 (80)

 No

19 (12)

14 (12)

 Unknown

11 (7)

9 (8)

 Unknown
Smoking

Histopathology
106 (66)

74 (65)

 SCC

45 (28)

32 (28)

 Others

10 (6)

8 (7)

 KRAS mutant

55 (47)

41 (50)

 KRAS wild type

46 (40)

36 (44)

 KRAS unknown

10 (9)

2 (2)

5 (4)

3 (4)

37 (23)

37 (32)

124 (77)
161

77 (68)
114

 Adenocarcinoma

Molecular status*

 EGFR, ALK or ROS1
mutant
Line of treatment
 First line
 Second or more
Total

*Molecular status was only examined in NSCLC with non-
squamous cell carcinoma histology (116 patients in full cohort and
82 in the PDL1 known group).
ALK, echinoderm microtubule-associated protein like-4-anaplastic
lymphoma kinase (EML4/ALK) fusion; ECOG, Eastern Cooperative
Oncology Group; EGFR, epidermal growth factor receptor; KRAS,
Kirsten Rat Sarcoma GTPase; NSCLC, non-small cell lung cancer;
PDL1, programmed death ligand; ROS1, echinoderm c-ros
oncogene 1 fusion; SCC, squamous cell carcinoma.

RESULTS
Patients characteristics
A total of 170 patients were recruited between May
2018 and June 2019. Nine patients were excluded: six
patients were excluded as they were receiving targeted
therapy or immunotherapy in combination with another
anticancer agent, one patient died from another cause
before reaching the response assessment period, and
two patients were lost to follow-up. A total of 161 patients
treated with pembrolizumab (n=37), nivolumab (n=72)
and atezolizumab (n=52) were included in the study.
line therapy,
Pembrolizumab was administered as first-
while atezolizumab or nivolumab were used as second-
line or subsequent lines of treatment. Patients’ characteristics and cancer histopathology in the studied cohort
were similar to the general NSCLC population, with most
of the patients being smokers (81%), men (56%), more

than 65 years old (57%) and had good performance
status (ECOG 0 to 1) (table 1). Adenocarcinoma was the
predominant lung histology (66%). KRAS mutation was
the predominant molecular alteration in the non-SCC
lung cancer, especially in the PDL1 known group. PDL1
status was available for 114 patients, of whom 61 patients
(54%) expressed PDL1 in more than 50% of tumor cells.
Standard of care at the time required that treatment with
first-line pembrolizumab was only allowed for patients
with a PDL1 TPS score of ≥50%. Hence, all patients in
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Figure 1 Effect of HLA-I/II homozygosity on OS and PFS in patients with NSCLC treated with anti-PD1/PD-L1 immunotherapy.
A and B, comparison of patients with homozygosity at one or more HLA-I loci on OS and PFS, respectively. C and D,
comparison of patients with homozygosity at one or more HLA-II loci on OS and PFS, respectively. Kaplan-Meier curves were
compared using log-rank analysis. HLA,human leukocyte antigen; NSCLC, non-small cell lung cancer; OS, overallsurvival; PD1/
PDL1, programmed cell death protein-1/programmed death ligand 1; PFS, progression free survival.

the PDL1 known group treated with pembrolizumab as
first-line therapy had their PDL1 expression tested and
demonstrated ≥50% PDL1 expression in tumor cells.
Those treated with nivolumab or atezolizumab in the
second-
line setting had TPS scores <50% or were not
tested for PDL1 expression. This explains the higher
proportion of first-
line therapy patients in the PDL1
known group. Overall, both groups had very similar characteristics (table 1).
Genomic HLA-
I homozygosity at one or more loci
prevalence was 20%, with a similar proportion (18%)
observed in the PDL1 group. The prevalence of genomic
HLA-II homozygosity at one or more loci was moderately
higher in the PDL1 known group, being 35% compared
with 33% in the full cohort (online supplemental table
1). Comparison of clinical characteristics between
patients with HLA homozygosity and those with maximal
heterozygosity did not reveal unevenness between groups
(online supplemental table 2).
Prognostic value of HLA homozygosity
Survival analysis showed that NSCLC patients who were
treated with single-agent immunotherapy and are homozygous at one or more HLA-I loci had reduced overall
survival, compared with those who are heterozygous at
all HLA-I loci (HR=1.96, 95% CI 1.02 to 3.78, p=0.04)
(figure 1A). The effect of homozygosity at one or more
4

HLA-
I loci trended towards improved PFS but it was
not statistically significant (figure 1B). However, we did
not find a statistically significant effect on OS or PFS,
when HLA zygosity was evaluated for HLA-A, HLA-B or
HLA-C separately (data not shown). Moreover, no statistically significant differences were observed in OS or
PFS between patients that were homozygous at one or
more HLA-II loci and those that were heterozygous at all
HLA-II loci (figure 1C,D).
Subgroup analysis suggested that homozygosity at one
or more HLA-I loci was associated with shorter survival
especially in patients older than 65, those who have high
ECOG status (≥2) and those treated with anti-PD1 rather
than anti-PDL1 immunotherapy (figure 2). In particular,
HLA homozygosity seemed to significantly affect the
survival of patients expressing PDL1 in more than 50%
of their tumor tissue (p<0.001). Kaplan-Meier curves of
PDL1 status-
based subgroups, revealed that the negative effect of HLA homozygosity on OS and PFS was only
statistically significant in the subgroup with more than
50% PDL1-expressing cells, and separation of the curves
was evident (HR=3.93, 95% CI 1.30 to 11.85, p<0.001)
(figure 3). The effect of HLA-I zygosity on OS among
patients with PDL1 ≥50% was driven by homozygosity in
HLA-A (HR=6.46, 95% CI 1.41 to 29.2, p=0.015, (online
supplemental figure 1). A very limited number of cases
Abed A, et al. J Immunother Cancer 2020;8:e001620. doi:10.1136/jitc-2020-001620
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at one or more HLA-I loci on PFS was only apparent after
controlling for interactions between PDL1 status and
HLA-I genotype (HR=2.18, 95% CI 1.02 to 4.66, p=0.043)
(table 2). No significant interactions were found between
HLA-I and the other variables (data not shown).
Prognostic value of HLA-I supertypes
We also investigated the clinical relevance of HLA-I supertypes on patient survival after treatment with anti-PD1/
PDL1 antibodies. Among the eight supertypes evaluated,
only HLA-A02 had a statistically significant association
with improved survival (HR=0.56, 95% CI 0.34 to 0.93,
p=0.023) (table 3, online supplemental figure 1). The
effect of homozygosity at one or more HLA-I loci among
PDL1 ≥50% group was driven by the presence of HLA-
A02 (HR=0.36, 95% CI 0.15 to 0.89, p=0.042) (online
supplemental figure 2). However, the multivariable analysis indicated that HLA-A02 status was not an independent prognostic variable (online supplemental table 3).

Figure 2 Association between HLA-I homozygosity and
OS. Subgroups were stratified according to age, sex, PDL1
tumor proportion score, pre-treatment neutrophil-lymphocyte
ratio (NLR), Eastern Cooperative Oncology Group (ECOG)
performance scores, smoking status, histopathology, the
presence of KRAS mutations (only among non-SCC cases),
therapy modality and line of treatment and analyzed using
of Cox regression. F,female; HLA,human leukocyte antigen;
M, male; OS, overall survival; PD1, programmed cell death
protein-1; PDL1,programmed death ligand; SCC, squamous
cell carcinoma.

were found homozygous for HLA-B or HLA-C (n=3 and
4, respectively), and therefore not suitable for statistical
analysis. No differences in OS or PFS were observed in
patients with PDL1 less than 50%, based on their HLA
genotype.
We carried out univariable and multivariable Cox
regression analyzes including other variables that may
affect survival in these patients (age, sex, PDL1 expression,
ECOG, NLR and therapy type (anti-PD1 and anti-PDL1))
(table 2). Homozygosity at one or more HLA-I loci and
type of checkpoint inhibitor used (anti-PD1 vs anti-PDL1)
were the only markers associated with OS in the univariable analysis (table 2). In the multivariable analysis, NLR
also emerged as a prognostic marker of OS together
with treatment type and HLA-I genotype. Notably, after
controlling for interaction between PDL1 and HLA-I in
the model, HLA-
I homozygosity emerged as having a
highly significant association with OS (HR=3.70, 95% CI
1.53 to 8.95, p=0.004). The adverse effect of homozygosity
Abed A, et al. J Immunother Cancer 2020;8:e001620. doi:10.1136/jitc-2020-001620

DISCUSSION
Tumor specific markers such as PDL1 expression, tumor
mutational burden and mismatch repair deficiency have
been described as predictors of long-
term benefit to
immune checkpoint inhibitor blockade.26 However, variations in outcomes can also be influenced by host-specific
factors. Chowell et al 2018 showed in a cohort of melanoma and patients with NSCLC treated with single-agent
anti-PD1 or in combination with anti-CTLA-4, that HLA-I
homozygosity at one or more loci was associated with
shorter survival comparing to those who were heterozygous at all HLA-I loci (HR=1.4). However, the study
did not demonstrate the effect of HLA homozygosity in
patients with NSCLC specifically. The results of our study
indicate that homozygosity at one or more HLA-I loci is
associated with poor outcomes in patients with NSCLC
treated with single-agent anti-PD1/PDL1 in the first-line
or the second-line setting.
HLA-I expression in cancer tissue was found to be a key
factor determining increased immune cell infiltration
into NSCLC tissue, and independent of PDL1 status.27
While there is enough evidence to suggest that downregulation of HLA-I molecule is one of the mechanisms used
by the tumor to escape the immune system,13 14 a coordinated balance needs to be achieved to avoid destruction
by natural killer cells (NK cells)28 and this might reduce
the impact of HLA-
I downregulation as a mechanism
to evade the immune system. On the other hand, loss
of heterozygosity in cancer tissue was found to be associated with poor treatment outcomes.29 30 However, loss
of genomic heterozygosity in tumor occurs only in 11%
of cases.23 As shown in our study, germline homozygosity
of HLA-I at one or more loci also has a clear impact on
survival, underscoring the role that HLA-I molecules play
on the immune response against NSCLC.
The effect of HLA-I homozygosity on survival was more
pronounced in patients with strong PDL1 expression
5
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Figure 3 Effect of HLA-I homozygosity on survival and progression free survival in patients with NSCLC treated with anti-PD1/
PDL1 immunotherapy based on their PDL1 status (≥50% vs <50%). A and B, association between homozygosity at one or more
HLA-I loci on OS and PFS, respectively, among patients whom their cancer express PDL1 in ≥50% of the cancer tissue. C and
D, association between homozygosity at one or more HLA-II loci on OS and PFS, respectively, among patients whom their
cancer express PDL1 in <50% of the cancer tissue. HLA, human leukocyte antigen; NSCLC, non-small cell lungcancer; OS,
overall survival; PD1/PDL1, programmed cell death protein-1/programmeddeath ligand 1; PFS, progression free survival.

(≥50%). The expression of PDL1 on tumor tissue, as an
immune regulatory mechanism has to be preceded by
an interaction between peptide/HLA-
I molecule and
T cell receptors. This implies that the expressed HLA-I
molecule is not downregulated in tumor cells and PDL1
expression is the primary mechanism of immune evasion
in these cases.27 Therefore, the HLA-I homozygosity may
have a profound impact on survival among patients with
PDL1 ≥50%, when treated with PD1/PDL1 inhibitors.
This also implies that patients with PDL1 <50% utilize
other immune evasion mechanisms, including downregulation of HLA in cancer cells.
Our results are in contrast with the report by Negrao et
al,24 which did not find a significant correlation between
HLA zygosity and survival in an NSCLC cohort treated
with PD-1/PDL1 at the M. D. Anderson Cancer Center.
Notably, a large proportion (25%) of their patient cohort
received anti-PD-1/PDL1 as third-line therapy, while all
our study participants were treated either in the first-line
or second-line setting. Moreover, their dichotomisation
for PDL1 expression was carried out based on 1% TPS,
while our subgroup analysis was based on a 50% PDL1
expression cut-off.
Chowell et al showed that the presence of HLA-B62
and HLA-B44 in patients with melanoma treated with
immune checkpoint inhibitors are associated with worse
6

(HR=2.29) and better prognosis (HR 0.61), respectively.
However, they did not evaluate the role of HLA supertypes
in their cohort of patients with NSCLC. In our cohort
of patients with NSCLC treated with anti-
PD1/PDL1
therapy, the presence of HLA-A02 supertype appears to
positively affect survival. This may reflect differences in
cancer biology between melanoma and NSCLC, which is
reflected by the degree of response to immunotherapy
and in particular to anti-CTLA4 agents. The differential effect of HLA supertypes in melanoma and NSCLC,
may also reflect the differences in the type of mutations
and therefore neoepitopes between these two cancers.31
HLA-A02 molecule binds small aliphatic and small hydrophobic/aliphatic amino acids in the B and F pockets,10
for example, KRAS G12V neoantigen represent the
tumor specific antigen bound to HLA-
A*02:01.32 This
might help predict the type of cancer neoantigens that
are associated with better survival among patients with
NSCLC treated with anti-PD1/PDL-1. HLA-B is usually
expressed more frequently on the cell surface compared
with HLA-A.33 Nevertheless, the beneficial effects in
survival outcomes observed for carriers of the HLA-A02
supertype suggest that NSCLC might escape this downregulation mechanism.
Homozygosity at one or more genomic HLA-II loci in
patients with NSCLC treated with single agent anti-PD1/
Abed A, et al. J Immunother Cancer 2020;8:e001620. doi:10.1136/jitc-2020-001620
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1.78
3.16

0.598
0.916
0.216
0.059
<0.001

Sex (M vs F)

PDL1 (≥50% vs <50%)

ECOG (≤1 vs ≥2)

NLR (≤5 vs >5)

2.93

0.780
0.347
0.426
0.626
<0.001

Sex (M vs F)

PDL1 (≥50% vs <50%)

ECOG (≤1 vs ≥2)

NLR (≤5 vs >5)

1.32

1.26

1.06

1.75

0.67

0.67

0.78

0.71

0.48

0.92

1.66

0.98

0.72

0.53

0.70

1.13
0.45

Lower

95% CI

4.88

1.86

2.58

2.06

1.59

1.30

2.86

5.99

3.24

3.51

1.77

1.88

4.17
1.51

Upper

<0.001

0.113

0.401

0.721

0.111

0.262

0.059

3.18

1.56

1.35

1.10

1.51

0.74

1.77

4.36

2.95

0.002
<0.001

1.81

0.81

1.70

2.19
0.67

HR

0.141

0.498

0.094

0.023
0.229

P value

Multivariable

1.84

0.90

0.67

0.66

0.91

0.43

0.98

2.18

1.51

0.82

0.43

0.91

1.12
0.34

Lower

95% CI

5.47

2.70

2.73

1.82

2.49

1.26

3.20

8.75

5.75

3.97

1.50

3.16

4.30
1.29

Upper

3.07
0.58

0.404

1.54

1.36

1.24

1.43

0.78

2.18

0.26

4.26

2.97

1.89

1.12

1.44

3.70
0.75

HR

<0.001

0.119

0.395

0.470

0.176

0.369

0.043

0.094

<0.001

0.001

0.113

0.755

0.254

0.004
0.400

P value

0.16

1.77

0.89

0.67

0.69

0.85

0.45

1.02

0.05

2.12

1.53

0.86

0.54

0.77

1.53
0.38

Lower

95% CI

Multivariable +interaction

2.10

5.32

2.67

2.75

2.23

2.38

1.34

4.66

1.26

8.59

5.76

4.17

2.35

2.71

8.95
1.47

Upper

ECOG, Eastern Cooperative Oncology Group; F, female; HLA, human leukocyte antigen; M, male; NLR, neutrophil/lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival;
PD1/PDL1, programmed cell death protein-1/programmed death ligand 1; PFS, progression free survival.

Therapy type (αPD1 vs αPDL1)
HLA-I*PDL1

1.13

0.352

Age (<65 vs ≥65)
0.79

0.093

1.62

1.63

0.97

HLA-I zygosity (hetero vs homo)

PFS

HLA-I*PDL1

Therapy type (αPD1 vs αPDL1)

2.17
0.83

0.020
0.534

HLA-I zygosity (hetero vs homo)
Age (<65 vs ≥65)
1.14

HR

Univariable

Univariable and multivariable Cox regression analysis (n=114)

P value

OS

Table 2
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Table 3 Association of HLA-I supertypes with overall
survival of NSCLC patients treated with anti-PD1/PDL1
HLA-I
supertype

Frequency N
(%)
HR (95% CI)

P value

A24
A01

38 (23.6)
71 (44.1)

1.34 (0.74 to 2.41)
0.95 (0.57 to 1.57)

0.295
0.834

A02

80 (49.7)

0.56 (0.34 to 0.93)

0.023

A03

84 (52.2)

1.27 (0.77 to 2.08)

0.356

B58

13 (8.1)

0.98 (0.40 to 2.43)

0.966

B62

30 (18.6)

1.55 (0.80 to 3.00)

0.137

B27

32 (19.9)

0.91 (0.55 to 1.49)

0.075

B44

90 (55.9)

0.83 (0.50 to 1.38)

0.470

B07

75 (46.6)

0.91 (0.55 to 1.49)

0.705

B08
A01/A24

37 (23)
13 (8.1)

1.11 (0.60 to 2.07)
1.29 (0.51 to 3.30)

0.724
0.548

HLA, human leukocyte antigen; ;NSCLC, non-small cell lung
cancer; PD1/PDL1, programmed cell death protein-1/programmed
death ligand 1.

PDL1 treatment did not demonstrate a direct influence
on survival and may require larger numbers to show its
impact. HLA-II molecule is rarely expressed on cancer
tissue and more likely expressed on antigen-presenting
cells.34 Its expression on tumor infiltrating lymphocytes
rather than NSCLC tissue is associated with better PFS
and OS.35 HLA-II is responsible for the activation of CD4+
helper T-lymphocytes which4 5 then help to activate B-cells
and CD8+T cells, as well as promote the induction of
memory CD8+T cell.36 37 The role of CD4+T cells is much
less understood than CD8+T cells in cancer biology.34 All
these factors potentially contributed to our observation of
a lack of statistically significant effect of homozygosity at
one or more HLA-II molecule on OS and PFS of patients
with NSCLC treated with single agent anti-PD1/PDL1.
A secondary observation from our analysis was that
anti-PD1 therapy had longer OS and PFS when compared
with anti-
PDL1 immunotherapy. This observation is
consistent with the meta-analysis conducted by Tartarone
et al 2019.38 However, the latter study only carried out
an indirect comparison and analyzed PFS only. We also
considered that the results might be largely biased by our
retrospective cohort, which included a large number of
long-term survivors who received nivolumab (anti-PD1).
However, in the absence of an interaction between the
type of therapy and genomic HLA-I, we believe that this
finding is unrelated to the main theme of this research
project.
Our study has some limitations that require discussion. We did not incorporate the role of tumor mutation
burden (TMB) in this analysis, which is thought to play a
role in response to immunotherapy.39 However, Chowell
et al 201823 showed that low TMB among patients with
melanoma did not predict but that rather had an additive effect in the prognostic value of genomic HLA-I in
8

survival. In addition, we had limited access to cancer
tissue and were unable to assess somatic loss of HLA-I
heterozygosity or HLA expression, which have been
correlated individually with shorter OS and PFS.23 40 For
some of our patients, a fine needle aspiration (FNA)
was utilized for assessment of PDL1 status and other
molecular testing. Limited tissue availability after PDL1
analysis and other molecular testing is a significant roadblock in the field. In fact, Hurkmans et al40 reported of
having to exclude 70% of the patients recruited due to
tissue inadequacy to perform HLA immunohistochemistry. Moreover, our study is unable to assess the role of
homozygosity at one or more HLA-I loci as a predictive
marker for response to anti-PD1/PDL1 among patients
with NSCLC. Finally, while our subgroup analysis showed
a strong association between HLA and survival in patients
with PDL1 ≥50% TPS, the small number of homozygous
events resulted in large CIs. Thus, more extensive studies
are needed to validate the clinical prognosis value of HLA
zygosity in NSCLC treated with anti-PD1/PDL1 therapy.
Our study provides enough evidence that genomic
homozygosity is associated with a worse prognosis in
patients with NSCLC treated with single-agent immunotherapy. This is of special importance in NSCLC which
often relies on FNA for diagnosis, and therefore tumor
material can be exhausted after performing mutational
profiling and PDL1 staining. We propose that, in addition to PDL1 TPS, HLA-I typing should be considered
as a non-invasive and cost-effective biomarker to guide
treatment personalisation. Given that patients with HLA-I
homozygosity are less likely to derive clinical benefit from
single-agent anti-PD1/PDL1 therapy, consideration of a
more aggressive treatment combinations may be needed
to improve their prognosis, especially among those with
PDL1 TPS of 50% or more.
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Supplementary Table 1: Genomic HLA-I and -II status in the full and PDL1 known cohorts.
Full cohort
PDL1 known group
N (%)

N (%)

Homozygous at one or more loci

32 (20)

21 (18)

Heterozygous at all loci

129 (80)

93 (82)

Homozygous at one or more loci

56 (35)

38 (33)

Heterozygous at all loci

105 (65)

76 (67)

Total

161

114

Genomic HLA-I

Genomic HLA-II

HLA: Human Leukocyte Antigen
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Supplementary Table 2: Clinical characteristics of patients by HLA genotype
HLA-I
Variable
Age
<65
≥65
Sex
Female
Male
Smoking
Yes
No
Unk
ECOG
1
>1
Unk
Histopathology
Adeno
SCC
Other
NLR
≥5
<5
Unk
PDL1 status
≥50%
<50%
Unk
Treatment modality
Anti-PD1
(Nivo/Pembro)
Anti-PDL1 (Atezo)
Treatment line
1st line
2nd line
KRAS mutant*
Mutant
Wild-type
Unk

P-value

Homozygous
N=32 (%)

Heterozygous
N=129 (%)

Total
N=161 (%)

13 (41)
19 (59)

56 (43)
73 (57)

69 (57)
92 (57)

10 (31)
22 (69)

61 (47)
68 (53)

71 (44)
90 (56)

29 (91)
2 (6)
1 (3)

102 (79)
17 (13)
10 (8)

131 (81)
19 (12)
11 (7)

26 (81)
6 (19)
0

110 (85)
17 (13)
2 (2)

136 (84)
23 (14)
2 (1)

23 (72)
9 (28)
0

83 (64)
36 (28)
10 (8)

106 (66)
45 (28)
10 (6)

14 (44)
18 (56)
0

47 (36)
81 (63)
1 (1)

61 (38)
99 (61)
1 (1)

9 (28)
12 (38)
11 (34)

52 (40)
41 (32)
36 (28)

61 (38)
53 (33)
47 (29)

21 (66)

88 (68)

109 (68)

11 (34)

41 (32)

52 (32)

8 (25)
24 (75)

29 (23)
100 (77)

37 (23)
124 (77)

13 (57)
11 (48)
3 (13)

42 (45)
35 (38)
7 (7)

55 (47)
46 (40)
10 (9)

HLA-II

P-value

Homozygous
N= 56 (%)

Heterozygous
N= 105 (%)

Total
N= 161 (%)

0.843

19 (34)
37 (66)

50 (48)
55 (52)

69 (57)
92 (57)

0.095

0.115

22 (39)
34 (61)

49 (47)
56 (53)

71 (44)
90 (56)

0.369

45 (80)
7 (13)
4 (7)

86 (82)
12 (11)
7 (7)

131 (81)
19 (12)
11 (7)

51 (91)
5 (9)

85 (81)
18 (17)
2 (2)

136 (84)
23 (14)
2 (1)

40 (71)
11 (20)
5 (9)

66 (63)
34 (32)
5 (5)

106 (66)
45 (28)
10 (6)

21 (38)
35 (62)
0

40 (38)
64 (61)
1 (1)

61 (38)
99 (61)
1 (1)

17 (30.5)
22 (39)
17 (30.5)

44 (42)
31 (30)
30 (28)

61 (38)
53 (33)
47 (29)

42 (75)

67 (64)

109 (68)

14 (25)

38 (36)

52 (32)

13 (23)
43 (77)

24 (23)
81 (77)

37 (23)
124 (77)

22 (49)
13 (29)
4 (15)

33 (46)
33 (46)
6 (8)

55 (47)
46 (40)
10 (9)

0.322

0.441

0.815

0.464

0.278

0.779

0.762

0.974

0.831

0.143

0.114

0.905

0.126

0.148

0.959

0.217

Unk – unknown, P-value of Chi-squared test, *KRAS mutation only examined in non-SCC NSCLC (5 patients with
targetable mutation were excluded from the table), Nivo: nivolumab, Pembro: Pembrolizumab.
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Supplementary Table 3: Univariable and multivariable Cox regression analysis for HLA-A02 (N=114)
Univariate
OS

p-value

HR

Multivariate
95.0% CI

Lower

Upper

p-value

HR

95.0% CI
Lower

Upper

HLA-A02 (positive vs negative)

0.025

0.56

0.34

0.93

0.242

0.67

0.34

1.31

Zygosity (hetero vs homo)

0.020

2.17

1.13

4.17

0.046

2.01

1.01

4.00

Age (<65 vs ≥65 )

0.534

0.83

0.45

1.51

0.301

0.70

0.36

1.38

Sex (M vs F)

0.598

1.14

0.69

1.88

0.191

1.53

0.81

2.91

PDL1 (≥50% vs <50%)

0.916

0.97

0.53

1.77

0.366

0.74

0.39

1.41

ECOG (≤1 vs ≥2)

0.216

1.63

0.72

3.51

0.201

1.69

0.76

3.76

NLR (≤5 vs >5)

0.059

1.78

0.98

3.24

0.001

2.97

1.53

5.76

Therapy type (αPD1 vs αPDL1)

<0.001

3.16

1.66

5.99

0.000

4.10

2.02

8.30
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Overall survival%
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Supplementary Figure 1: Effect of HLA-A homozygosity on overall and progression-free
survival in NSCLC patients with PDL1 ≥50% (N=68) treated with anti-PD1/PDL1
immunotherapy.
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Supplementary Figure 2: Effect of HLA-A and HLA-B supertypes on overall survival in NSCLC
patients treated with anti-PD1/PDL1 immunotherapy.
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Supplementary Figure 3: Effect of the presence of HLA-A02 on OS(A) and PFS(B) in NSCLC
patients treated with anti-PD1/PDL1 immunotherapy with PDL1 expression ≥50%.
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